Sagimet Biosciences Inc.
Close on Oct 19, 2026
- Market cap
- $470.59M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | Before market open | – | $-0.33 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 11, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 13, 2025 | Before market open | – | $-0.32 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 12, 2025 | Before market open | – | $-0.50 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | Before market open | – | $-0.25 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 15, 2024 | Before market open | – | $-0.23 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 24, 2024 | Before market open | – | – | – |
Press releases
Announcements Sagimet Biosciences filed with the SEC
Forward-Looking Statements and Disclaimer This presentation contains
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Sagimet Announces Positive Full 52-Week Results from License
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Sagimet Biosciences Reports Second Quarter 2026 Financial Results and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Novel Therapeutics August 2026 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Forward-Looking Statements and Disclaimer This presentation contains
Regulation FD disclosure · EX-99.1 to Form 8-K
Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K
This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation
Regulation FD disclosure · EX-99.1 to Form 8-K
Confidential and proprietary information of Sagimet Biosciences Inc.
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Provides Strategic and Corporate Updates
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Sagimet Biosciences Reports Fourth Quarter
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Targeting Metabolic Dysfunction with Novel Therapies to Treat M ASH, Acne & Cancer March 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Sagimet Announces Positive 52-Week Data from
Regulation FD disclosure · EX-99.1 to Form 8-K
with Novel Therapies to Treat
Regulation FD disclosure · EX-99.2 to Form 8-K
with Novel Therapies to Treat
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Sagimet Biosciences Announces Positive Results
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination
Other events · EX-99.1 to Form 8-K
Sagimet Biosciences Reports Third Quarter 2025
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Targeting Metabolic Dysfunction with Novel Therapies to Treat M ASH, Acne & Cancer November 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
with Novel Therapies to Treat
Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Targeting Metabolic Dysfunction with Novel Therapies to Treat M ASH, Acne & Cancer August 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Sagimet Biosciences Announces Positive Phase
Regulation FD disclosure · EX-99.1 to Form 8-K
Sagimet Biosciences Reports First Quarter 2025
Results of operations · Other events · EX-99.1 to Form 8-K
Targeting Metabolic Dysfunction with Novel Therapies to Treat M ASH, Acne & Cancer May 2025
Results of operations · Other events · EX-99.2 to Form 8-K
Sagimet Biosciences Reports Full Year 2024 Financial
Results of operations · Other events · EX-99.1 to Form 8-K
Targeting Metabolic Dysfunction with Novel Therapies to Treat M ASH, Acne & Cancer March 2025
Results of operations · Other events · EX-99.2 to Form 8-K
Sagimet Biosciences Announces Clearance of IND
Other events · EX-99.1 to Form 8-K
Targeting Metabolic Dysfunction with Novel Therapies to Treat M ASH, Acne & Cancer February 2025
Other events · EX-99.1 to Form 8-K
Targeting Metabolic Dysfunction with Novel Therapies to Treat M ASH, Acne & Cancer January 2025
Other events · EX-99.1 to Form 8-K
Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Sagimet Biosciences Reports Second Quarter 2024
Results of operations · Other events · EX-99.1 to Form 8-K
Targeting Metabolic Dysfunction with Novel Therapies to Treat M ASH, Acne & Cancer August 2024
Results of operations · Other events · EX-99.2 to Form 8-K
Targeting Metabolic Dysfunction with Novel Therapies to Treat M ASH, Acne & Cancer July 2024
Other events · EX-99.1 to Form 8-K
Sagimet Biosciences Presents Data from ITT and
Other events · EX-99.1 to Form 8-K/A
Biosciences Presents Data from ITT and F3 Patient Population in Phase
Shareholder vote results · Other events · EX-99.1 to Form 8-K
Targeting Metabolic Dysfunction with Novel Therapies to Treat M ASH, Acne and Cancer May 202 4
Regulation FD disclosure · EX-99.1 to Form 8-K
Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Sagimet Biosciences Reports Full Year 2023
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Targeting Metabolic Dysfunction with Novel Therapies to Treat M ASH, Acne and Cancer March 202 4
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
of Public Offering of Series A Common Stock
Other events · EX-99.1 to Form 8-K